Abel Hall LLC’s Neumora Therapeutics NMRA Stock Holding History

Abel Hall LLC’s Portfolio NMRA Stock Details NMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$23.8K	Buy	+39,839	New	+$55.1K	﹤0.01%	866

Other funds holding NMRA

Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return

Addis & Hill Wayne, Pennsylvania $181M AUM 13.54% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

Legacy Private Trust Neenah, Wisconsin $1.83B AUM 13% 1-Year Est. Return

ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $57B AUM 43.56% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

GF Fund Management Guangzhou, China $7.72B AUM 122.96% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Abel Hall LLC's NMRA Position: Q3 2026 in Review

Abel Hall LLC opened a new position in Neumora Therapeutics (NMRA) in Q3 2026: 39,839 shares worth $23.8K. The stake represents ﹤0.01% of the portfolio and ranks #866 among its holdings.

22 funds tracked by Wall St. Rank hold NMRA as of Q3 2026.

Abel Hall LLC held 39,839 shares of Neumora Therapeutics worth $23.8K as of Q3 2026.
Neumora Therapeutics was a new Abel Hall LLC position in Q3 2026.
Neumora Therapeutics made up ﹤0.01% of Abel Hall LLC's portfolio in Q3 2026, its #866 holding.
22 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q3 2026.

Based on Abel Hall LLC's 13F filing for Q3 2026, filed 19 Oct 2026.